Compare SOUNW & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOUNW | DVAX |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | 842 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.3B |
| IPO Year | N/A | 2004 |
| Metric | SOUNW | DVAX |
|---|---|---|
| Price | $4.90 | $10.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 104.1K | ★ 1.5M |
| Earning Date | 02-27-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $67,297,000.00 | ★ $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | N/A | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 76.05 | 26.73 |
| 52 Week Low | $4.84 | $9.20 |
| 52 Week High | $6.16 | $14.63 |
| Indicator | SOUNW | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.78 | 48.59 |
| Support Level | $4.85 | $10.71 |
| Resistance Level | $5.44 | $11.00 |
| Average True Range (ATR) | 0.38 | 0.26 |
| MACD | 0.11 | -0.06 |
| Stochastic Oscillator | 52.87 | 22.63 |
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.